Head and neck cancer trials in Belgium
37 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleLYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.
- Where
- Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Centre Leon Berard
See details and how to join2022-501315-13-00 · EU 2022-501315-13-00 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Brussels, Charleroi, Leuven
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Edegem, La Louvière, Leuven, Sint-Lambrechts-Woluwe, Sint-Niklaas
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 1/2Taking peopleA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Where
- Anderlecht, Gent, Namur, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 560 worldwide
- Run by
- Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Antwerp, Brugge, Mons, Namur, Sint-Niklaas, Yvoir
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2/3Taking peopleOrdastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Where
- Edegem, Jette, Namur, Sint-Niklaas
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT06295731 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Brussels, Edegem, Ghent, Jette, Leuven
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Charleroi, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 2Not yet taking people in BelgiumPhase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy
- Where
- Anderlecht, Charleroi, Gent, Jette, La Louvière, Leuven, Liège, Namur, Sint-Lambrechts-Woluwe, Sint-Niklaas
- Age
- 18 years and over
- People
- 153
- Run by
- Cliniques Universitaires Saint-Luc
See details and how to join2025-523575-36-00 · EU 2025-523575-36-00 - Phase 2Taking peopleA Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Where
- Gent, Namur, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT07807163 · EU 2026-526741-10-00 - Phase 3Taking peopleA Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Where
- Edegem, Ghent, Leuven, Sint-Niklaas, Woluwe-Saint-Lambert
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00 - No phaseNot yet taking people in BelgiumRehabilitation Through Individualized Support and Exercise
- Where
- Leuven
- Age
- 18 years and over
- People
- 39
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT07857096 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Kortrijk
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Charleroi, Edegem, Jette, La Louvière, Namur
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 1Taking peopleA Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
- Where
- Edegem, Hasselt, Leuven
- Age
- 18 years and over
- People
- 93 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to joinNCT05007782 · EU 2022-501684-40-00 - No phaseTaking peopleTo Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
- Where
- Aalst, Ghent
- Age
- 18 years and over
- People
- 850 worldwide
- Run by
- XEOS Medical
See details and how to joinNCT06970275 - Phase 1/2Taking peopleStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Where
- Antwerp, Brussels, Liège
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655 - Phase 1/2Taking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Anderlecht, Leuven
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Anderlecht
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Anderlecht, Leuven
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 3Taking peoplePembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
- Where
- Antwerp, Genk, Hasselt, Kortrijk, La Louvière, Namur, Sint-Lambrechts-Woluwe, Sint-Niklaas
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT05815927 · EU 2023-504478-39-00 - Phase 3Taking peopleA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Where
- Charleroi, Edegem, Gent, Liège, Namur, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 864 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06256588 · EU 2023-508613-17-00 - Phase 3Taking peopleStudy Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
- Where
- Charleroi
- Age
- 18 years to 80 years
- People
- 780 worldwide
- Run by
- Groupe Oncologie Radiotherapie Tete et Cou
See details and how to joinNCT07264075 · EU 2025-522996-27-00 - No phaseNot yet taking people in BelgiumAI-Assisted Endoscopy for Upper Aerodigestive Tract Lesions
- Where
- Leuven
- Age
- 18 years and over
- People
- 283 worldwide
- Run by
- Istituto Italiano di Tecnologia
See details and how to joinNCT07596355 - Phase 3Taking peopleA Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Where
- Liège, Namur, Sint-Niklaas
- Age
- 18 years and over
- People
- 410 worldwide
- Run by
- AVEO Pharmaceuticals, Inc.
See details and how to joinNCT06064877 · EU 2023-505606-42-00